References
- Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 82(5), 488–496 (2004).
- Petrovsky N, Heinzel S, Honda Y, Lyons AB. New-age vaccine adjuvants: friend or foe? Biopharm. Int. 20, 24–33 (2007).
- Schijns VE, Tangerås A. Vaccine adjuvant technology: from theoretical mechanisms to practical approaches. Dev. Biol. (Basel). 121, 127–134 (2005).
- Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54(Pt. 1), 1–13 (1989).
- Glenn AT, Pope CG, Waddington H, Wallace V. The antigenic value of toxoid precipitated by potassium-alum. J. Pathol. Bacteriol. 29, 38–45 (1926).
- Matzinger P. The danger model: a renewed sense of self. Science 296(5566), 301–305 (2002).
- Brewer JM, Alexander J. Cytokines and the mechanisms of action of vaccine adjuvants. Cytokines Cell. Mol. Ther. 3(4), 233–246 (1997).
- Petrovsky N. Freeing vaccine adjuvants from dangerous immunological dogma. Expert Rev. Vaccines 7(1), 7–10 (2008).
- Carlson BC, Jansson AM, Larsson A, Bucht A, Lorentzen JC. The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats. Am. J. Pathol. 156(6), 2057–2065 (2000).
- Beck FW, Whitehouse MW, Pearson CM. Improvements for consistently inducing experimental allergic encephalomyelitis (EAE) in rats: I. without using mycobacterium. II inoculating encephalitogen into the ear. Proc. Soc. Exp. Biol. Med. 151(3), 615–622 (1976).
- Waters RV, Terrell TG, Jones GH. Uveitis induction in the rabbit by muramyl dipeptides. Infect. Immun. 51(3), 816–825 (1986).
- Lerner EM 2nd, Mcmaster PR, Exum ED. the course of experimental autoallergic thyroiditis in inbred guinea pigs. the pathologic changes and their relationship to the immune response over a 2 year period. J. Exp. Med. 119, 327–342 (1964).
- Nohynek H, Jokinen J, Partinen M et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 7(3), e33536 (2012).
- Partinen M, Saarenpaa-Heikkila O, Ilveskloski I. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One 7, e33723 (2012).
- Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 49(3), 177–184 (2003).
- Gherardi RK, Coquet M, Chérin P et al. Macrophagic myofasciitis: an emerging entity. Groupe d’Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l’Association Française contre les Myopathies (AFM). Lancet 352(9125), 347–352 (1998).
- Gherardi RK, Coquet M, Cherin P et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 124(Pt 9), 1821–1831 (2001).
- Li H, Willingham SB, Ting JP, Re F. Cutting edge: inflammasome activation by alum and alum’s adjuvant effect are mediated by NLRP3. J Immunol. 181, 17–21 (2008).
- Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat. Genet. 29(3), 301–305 (2001).
- Cooper PD, Petrovsky N. Delta inulin: a novel, immunologically active, stable packing structure comprising ß-D-[2–>1] poly(fructo-furanosyl) a-D-glucose polymers. Glycobiology 21(5), 595–606 (2011).
- Cristillo AD, Ferrari MG, Hudacik L et al. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. J. Gen. Virol. 92(Pt. 1), 128–140 (2011).
- Eckersley AM, Petrovsky N, Kinne J, Wernery R, Wernery U. Improving the dromedary antibody response: the hunt for the ideal camel adjuvant. J. Camel Pract. And Res. 18, 35–46 (2011).
- Gordon DL, Sajkov D, Woodman RJ et al. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax polysaccharide adjuvant. Vaccine 30, 5407–5016 (2012).
- Layton RC, Petrovsky N, Gigliotti AP et al. Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets. Vaccine 29(37), 6242–6251 (2011).
- Lobigs M, Pavy M, Hall RA et al. An inactivated vero cell-grown Japanese encephalitis vaccine formulated with advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. J. Gen. Virol. 91(Pt. 6), 1407–1417 (2010).